EGFR and melanoma: Only 3 (6.4%) of the identified 47 CDx devices contained therapeutic class labeling, with two devices targeting EGFR mutations for the treatment of NSCLC and one targeting BRAF V600E and BRAF/MEK inhibitor combinations for melanoma.